FORGE Life Science is now Evrys Bio. Read more
FORGE Life Science secures $1.0 M in bridge financing from its strategic investors.
FORGE Life Science Head of Biology, Eain Murphy, presents, “Targeting Host-cell Metabolism to Address Respiratory Viruses”, at the 6th International Society for Influenza and Other Respiratory Virus Diseases (ISIRV) Antiviral Group Conference – Advanced Respiratory Virus Therapeutics, Rockville, MD.
FORGE Life Science is awarded its first Department of Defense STTR contract (W911QY18P0300) from the Joint Project Manager Medical Countermeasure Systems. Proposal titled, “Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum Medical Countermeasure Against Marburg Virus”.
FORGE Life Science CEO, Lillian Chiang, presents at the National Institutes of Health CMV Workshop, Cytomegalovirus Infection: Advancing Strategies for Prevention and Treatment.
The European Patent Office grants patent EP 2670404 B1, allowing claims directed to antiviral treatments with inhibitors of two or more sirtuins. This I.P. is exclusively licensed by FORGE from Princeton University. Read more
FORGE Life Science CEO, Lillian Chiang, presents at the Military Health System Research Symposium, Kissimmee, FL. Read more